
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
15.12.2025 | 1 Std. 7 Min.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Ep190: Neil Kumar on Building a Rare Disease Drug Company
20.11.2025 | 1 Std. 13 Min.
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
12.11.2025 | 1 Std. 12 Min.
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Ep188: Art Krieg on Innate Immune System Activators for Cancer
28.10.2025 | 1 Std. 9 Min.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Ep187: Eric Fischer on Creating a New Class of Medicines
14.10.2025 | 1 Std. 5 Min.
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.



The Long Run with Luke Timmerman